

UK Disclosure Certification 2020

Portola Pharmaceuticals, Inc continues to work with various partners in healthcare in order to research, develop, publish, and commercialize its product. Healthcare professionals (HCPs) and healthcare organizations (HCOs) provide us and our industry with valuable, independent and expert knowledge derived from their clinical and management experience. Our goal is to collaborate and work with these experts, share our findings, rely on their feedback, and ultimately work towards our mutual goal of benefiting patients.

Throughout the medicines life cycle pharmaceutical companies work with scientists and HCPs. These collaborations are essential in addressing patient needs.

EFPIA and its member associations codes provide requirements and guidelines detailing that the interactions of pharmaceutical companies with HCPs and HCOs meet the high standards of integrity and transparency. Building greater transparency to the relationships between pharmaceutical companies and HCPs/HCOs aims to building understanding of the collaboration and recognition of its value to patient care.

Except in countries where disclosure is prescribed by laws, Portola Pharmaceuticals hereby confirms that its disclosures of transfers of value (ToVs) to HCPs and HCOs made in 2019 have been reported in application of the EFPIA Disclosure Code following key principles:

Disclosure quality Portola Pharmaceuticals certifies that:

- For 2019, disclosures will be made in each country its products were made available,
- Its disclosures include direct and indirect ToVs, as defined in the codes and associated guidance issued by EFPIA;
- Its Methodological Note describes the process it has followed in order to compile the data hereby disclosed. Methodology used for the collection and organization of ToVs is in line with the EFPIA Disclosure Code's requirements and applicable codes Portola Pharmaceuticals certifies that:
- Data collection complies with the requirements of the EFPIA Disclosure Code; and
- Where required, consent for publication of this data was obtained from the relevant HCPs and HCOs;
- Where consent was not attained, payments have been aggregated and reported in line with the guidance provided by the relevant country code

Aggregate disclosures are limited to Research and Development ToVs and such ToVs that cannot be disclosed on an individual basis for legal reasons Portola Pharmaceuticals certifies that aggregate disclosure is limited to the following topics:

- Research and Development Transfers of Value (as defined in the EFPIA Disclosure Code);
- Transfers of Value to Recipients that have opposed to the publication on grounds of the protection of their private data;
- If an HCP or HCO (where applicable) has provided consent to individual disclosure only in respect of part of the Transfers of Value he/she/it received, all Transfers of Value to such HCP or HCO (where applicable) are being disclosed in the aggregate.

Portola Pharmaceuticals certifies that its disclosure complies with the Data Privacy Obligations.

Note: Due to restrictions placed on our business during the COVID-19 pandemic and accommodations made by the UK ABPI, the addition of the UK transparency report has been published on our website in the aggregate.